There is little doubt that the arrival of COVID-19 changed the game for communication and commercialisation efforts for pharmaceutical companies around the world.
Stakeholder expectations are high and, with all eyes on healthcare at the moment, it is essential for companies to go beyond generic commitments, says Rosanna Campbell-Gray.
The company’s senior vice president for major markets (Europe, Canada and Japan) talks about the continued evolution of pharma’s approach to communications and commercialisation.
Patient centricity has become a key aspiration for the pharma industry over the last several years, but getting entire organisations to think and behave in a patient-centric way can be chal
The atrial fibrillation (AFib) detection feature on Apple Watch devices has become the first digital health technology to be qualified under a programme recently introduce
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.